Survival outcomes of giant cell glioblastoma: Institutional experience in the management of 20 patients

Taemin Oh, Martin J. Rutkowski, Michael Safaee, Matthew Z. Sun, Eli T. Sayegh, Orin Bloch, Tarik Tihan, Andrew T. Parsa

Research output: Contribution to journalArticle

Abstract

Giant cell glioblastoma (GCG) is a rare subtype of glioblastoma (GBM) that is believed to carry an improved prognosis. However, given the rarity of this tumor, best management practices for GCG have yet to be ascertained. Here, we present our experience in managing GCG tumors at the University of California, San Francisco. Patients were retrospectively identified through chart review, and data pertaining to patient demographics, treatment plans, and follow-up were extracted from existing medical records. Overall survival (OS) and progression-free survival (PFS) were the primary and secondary endpoints, respectively. In sum, we identified 22 patients who were managed or followed for GCG. Most patients (78%) initially underwent subtotal resection as primary treatment for their tumor, and most also received post-operative adjuvant therapy (90%), with radiation being the most frequently administered modality (85%). Within this institutional cohort, median OS and PFS were 15.4 months and 5.7 months, respectively. On multivariate survival analysis, age (p = 0.84), sex (p = 0.05), and adjuvant radiation plus temozolomide (p = 0.12) were not associated with prolonged OS. However, adjuvant radiation plus temozolomide was associated with longer PFS (p = 0.01), and patients receiving this therapy demonstrated a median PFS of 32.9 months versus 13.1 months. These findings confirm the comparatively improved prognosis of GCG over GBM. Moreover, they suggest that extent of resection may not significantly delay recurrence or extend survival, and that combination radiation with temozolomide may represent the optimum adjuvant paradigm to delay tumor progression.

Original languageEnglish (US)
Pages (from-to)2129-2134
Number of pages6
JournalJournal of Clinical Neuroscience
Volume21
Issue number12
DOIs
StatePublished - Dec 2014
Externally publishedYes

Fingerprint

Glioblastoma
temozolomide
Survival
Disease-Free Survival
Radiation
Giant Cell Tumors
Neoplasms
San Francisco
Therapeutics
Survival Analysis
Practice Guidelines
Medical Records
Multivariate Analysis
Demography
Recurrence

Keywords

  • Adjuvant
  • Cancer
  • Giant cell glioblastoma
  • Recurrence
  • Resection
  • Survival
  • Temozolomide

ASJC Scopus subject areas

  • Surgery
  • Neurology
  • Clinical Neurology
  • Physiology (medical)

Cite this

Oh, T., Rutkowski, M. J., Safaee, M., Sun, M. Z., Sayegh, E. T., Bloch, O., ... Parsa, A. T. (2014). Survival outcomes of giant cell glioblastoma: Institutional experience in the management of 20 patients. Journal of Clinical Neuroscience, 21(12), 2129-2134. https://doi.org/10.1016/j.jocn.2014.04.011

Survival outcomes of giant cell glioblastoma : Institutional experience in the management of 20 patients. / Oh, Taemin; Rutkowski, Martin J.; Safaee, Michael; Sun, Matthew Z.; Sayegh, Eli T.; Bloch, Orin; Tihan, Tarik; Parsa, Andrew T.

In: Journal of Clinical Neuroscience, Vol. 21, No. 12, 12.2014, p. 2129-2134.

Research output: Contribution to journalArticle

Oh, T, Rutkowski, MJ, Safaee, M, Sun, MZ, Sayegh, ET, Bloch, O, Tihan, T & Parsa, AT 2014, 'Survival outcomes of giant cell glioblastoma: Institutional experience in the management of 20 patients', Journal of Clinical Neuroscience, vol. 21, no. 12, pp. 2129-2134. https://doi.org/10.1016/j.jocn.2014.04.011
Oh, Taemin ; Rutkowski, Martin J. ; Safaee, Michael ; Sun, Matthew Z. ; Sayegh, Eli T. ; Bloch, Orin ; Tihan, Tarik ; Parsa, Andrew T. / Survival outcomes of giant cell glioblastoma : Institutional experience in the management of 20 patients. In: Journal of Clinical Neuroscience. 2014 ; Vol. 21, No. 12. pp. 2129-2134.
@article{60006bf4c7c04f70a7897e104cf3ec3e,
title = "Survival outcomes of giant cell glioblastoma: Institutional experience in the management of 20 patients",
abstract = "Giant cell glioblastoma (GCG) is a rare subtype of glioblastoma (GBM) that is believed to carry an improved prognosis. However, given the rarity of this tumor, best management practices for GCG have yet to be ascertained. Here, we present our experience in managing GCG tumors at the University of California, San Francisco. Patients were retrospectively identified through chart review, and data pertaining to patient demographics, treatment plans, and follow-up were extracted from existing medical records. Overall survival (OS) and progression-free survival (PFS) were the primary and secondary endpoints, respectively. In sum, we identified 22 patients who were managed or followed for GCG. Most patients (78{\%}) initially underwent subtotal resection as primary treatment for their tumor, and most also received post-operative adjuvant therapy (90{\%}), with radiation being the most frequently administered modality (85{\%}). Within this institutional cohort, median OS and PFS were 15.4 months and 5.7 months, respectively. On multivariate survival analysis, age (p = 0.84), sex (p = 0.05), and adjuvant radiation plus temozolomide (p = 0.12) were not associated with prolonged OS. However, adjuvant radiation plus temozolomide was associated with longer PFS (p = 0.01), and patients receiving this therapy demonstrated a median PFS of 32.9 months versus 13.1 months. These findings confirm the comparatively improved prognosis of GCG over GBM. Moreover, they suggest that extent of resection may not significantly delay recurrence or extend survival, and that combination radiation with temozolomide may represent the optimum adjuvant paradigm to delay tumor progression.",
keywords = "Adjuvant, Cancer, Giant cell glioblastoma, Recurrence, Resection, Survival, Temozolomide",
author = "Taemin Oh and Rutkowski, {Martin J.} and Michael Safaee and Sun, {Matthew Z.} and Sayegh, {Eli T.} and Orin Bloch and Tarik Tihan and Parsa, {Andrew T.}",
year = "2014",
month = "12",
doi = "10.1016/j.jocn.2014.04.011",
language = "English (US)",
volume = "21",
pages = "2129--2134",
journal = "Journal of Clinical Neuroscience",
issn = "0967-5868",
publisher = "Churchill Livingstone",
number = "12",

}

TY - JOUR

T1 - Survival outcomes of giant cell glioblastoma

T2 - Institutional experience in the management of 20 patients

AU - Oh, Taemin

AU - Rutkowski, Martin J.

AU - Safaee, Michael

AU - Sun, Matthew Z.

AU - Sayegh, Eli T.

AU - Bloch, Orin

AU - Tihan, Tarik

AU - Parsa, Andrew T.

PY - 2014/12

Y1 - 2014/12

N2 - Giant cell glioblastoma (GCG) is a rare subtype of glioblastoma (GBM) that is believed to carry an improved prognosis. However, given the rarity of this tumor, best management practices for GCG have yet to be ascertained. Here, we present our experience in managing GCG tumors at the University of California, San Francisco. Patients were retrospectively identified through chart review, and data pertaining to patient demographics, treatment plans, and follow-up were extracted from existing medical records. Overall survival (OS) and progression-free survival (PFS) were the primary and secondary endpoints, respectively. In sum, we identified 22 patients who were managed or followed for GCG. Most patients (78%) initially underwent subtotal resection as primary treatment for their tumor, and most also received post-operative adjuvant therapy (90%), with radiation being the most frequently administered modality (85%). Within this institutional cohort, median OS and PFS were 15.4 months and 5.7 months, respectively. On multivariate survival analysis, age (p = 0.84), sex (p = 0.05), and adjuvant radiation plus temozolomide (p = 0.12) were not associated with prolonged OS. However, adjuvant radiation plus temozolomide was associated with longer PFS (p = 0.01), and patients receiving this therapy demonstrated a median PFS of 32.9 months versus 13.1 months. These findings confirm the comparatively improved prognosis of GCG over GBM. Moreover, they suggest that extent of resection may not significantly delay recurrence or extend survival, and that combination radiation with temozolomide may represent the optimum adjuvant paradigm to delay tumor progression.

AB - Giant cell glioblastoma (GCG) is a rare subtype of glioblastoma (GBM) that is believed to carry an improved prognosis. However, given the rarity of this tumor, best management practices for GCG have yet to be ascertained. Here, we present our experience in managing GCG tumors at the University of California, San Francisco. Patients were retrospectively identified through chart review, and data pertaining to patient demographics, treatment plans, and follow-up were extracted from existing medical records. Overall survival (OS) and progression-free survival (PFS) were the primary and secondary endpoints, respectively. In sum, we identified 22 patients who were managed or followed for GCG. Most patients (78%) initially underwent subtotal resection as primary treatment for their tumor, and most also received post-operative adjuvant therapy (90%), with radiation being the most frequently administered modality (85%). Within this institutional cohort, median OS and PFS were 15.4 months and 5.7 months, respectively. On multivariate survival analysis, age (p = 0.84), sex (p = 0.05), and adjuvant radiation plus temozolomide (p = 0.12) were not associated with prolonged OS. However, adjuvant radiation plus temozolomide was associated with longer PFS (p = 0.01), and patients receiving this therapy demonstrated a median PFS of 32.9 months versus 13.1 months. These findings confirm the comparatively improved prognosis of GCG over GBM. Moreover, they suggest that extent of resection may not significantly delay recurrence or extend survival, and that combination radiation with temozolomide may represent the optimum adjuvant paradigm to delay tumor progression.

KW - Adjuvant

KW - Cancer

KW - Giant cell glioblastoma

KW - Recurrence

KW - Resection

KW - Survival

KW - Temozolomide

UR - http://www.scopus.com/inward/record.url?scp=84922788245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922788245&partnerID=8YFLogxK

U2 - 10.1016/j.jocn.2014.04.011

DO - 10.1016/j.jocn.2014.04.011

M3 - Article

C2 - 25037316

AN - SCOPUS:84922788245

VL - 21

SP - 2129

EP - 2134

JO - Journal of Clinical Neuroscience

JF - Journal of Clinical Neuroscience

SN - 0967-5868

IS - 12

ER -